This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Eastern Cooperative Oncology Group
ClinicalTrials.gov Identifier:
NCT01385150
First received: June 28, 2011
Last updated: May 18, 2017
Last verified: May 2017
June 28, 2011
May 18, 2017
January 3, 2012
February 3, 2012   (Final data collection date for primary outcome measure)
Absence of serum 2HG in all samples without an IDH mutation [ Time Frame: 1 day ]
Absence of serum 2HG in all samples without an IDH mutation
Complete list of historical versions of study NCT01385150 on ClinicalTrials.gov Archive Site
Relationship between 2HG level and survival outcomes [ Time Frame: 1 day ]
Relationship between 2HG level and survival outcomes
Not Provided
Not Provided
 
Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia
Analysis of Serum 2-Hydroxyglutarate (2HG) Levels, IDH Mutations and Clinical Outcome in Acute Myeloid Leukemia (AML)

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify and lean more about biomarkers related to cancer.

PURPOSE: This research study is studying biomarkers in blood samples from patients with acute myeloid leukemia.

OBJECTIVES:

Primary

  • To determine if serum 2-hydroxyglutarate (2HG) is only detected in acute myeloid leukemia (AML) patients with isocitrate dehydrogenase (IDH) mutations.

Secondary

  • To determine if the level of serum 2HG impacts leukemia-free survival (LFS).
  • To determine if the level of serum 2HG impacts overall survival (OS).
  • To determine if serum 2HG is undetectable at the time of documented clinical remission (CR) in IDH-mutated patients.

OUTLINE: Archived serum samples are analyzed for 2-hydroxyglutarate expression by reverse-phase liquid chromatography coupled to mass spectrometry. Results are then compared with presence or absence of an IDH mutation, patients' clinical outcome, as well as age, sex, white blood cell count at diagnosis, platelet count, bone marrow blast percentage at diagnosis, circulating (serum) percentage at diagnosis, cytogenetic risk group, presence of FLT3, NPMN1, and/or TET2 mutations, specific IDH mutation, and randomization treatment group allocation.

Observational
Observational Model: Other
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
Samples from patients enrolled on E1900 from whom samples were submitted for research
Leukemia
  • Genetic: mutation analysis
  • Genetic: protein analysis
  • Other: laboratory biomarker analysis
  • Other: liquid chromatography
  • Other: mass spectrometry
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
220
February 3, 2012
February 3, 2012   (Final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Morphologically confirmed acute myeloid leukemia (AML)

    • Newly diagnosed with AML
    • Serum samples from patients enrolled on the ECOG-1900 clinical trial between 2002 and 2008
    • Patients with or without isocitrate dehydrogenase (IDH) mutations

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Received 2 different doses of standard induction chemotherapy on ECOG-1900
Sexes Eligible for Study: All
17 Years to 60 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01385150
CDR0000702952
ECOG-E1900T8
Not Provided
Not Provided
Not Provided
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Courtney DiNardo, MD Abramson Cancer Center of the University of Pennsylvania
Eastern Cooperative Oncology Group
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP